Generation and validation of a prognostic score to predict outcome after re-irradiation of recurrent glioma.
Combs SE, Edler L, Rausch R, Welzel T, Wick W, Debus J.
Acta Oncol. 2013 Jan;52(1):147-52.
Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood.
Massimino M, Biassoni V, Miceli R, Schiavello E, Warmuth-Metz M, Modena P, Casanova M, Pecori E, Giangaspero F, Antonelli M, Buttarelli FR, Potepan P, Pollo B, Nunziata R, Spreafico F, Podda M, Anichini A, Clerici CA, Sardi I, De Cecco L, Bode U, Bach F, Gandola L.
In this case the patient recurred after 4 months of radiation. It is always advisable to wait for at least one year before re-irradiation. We have evidence from glioma as well as head and neck tumor that patients who are recurring early are unlikely to be have benefit of re-irradiation and toxicity may be higher. A feasible option is metronomic temozolomide.